NCT04718740 2023-08-14
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
Clinical Trials
10 trialsNCT03945604 2022-08-12
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT04108676 2022-07-29
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03075462 2022-07-01
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03509636 2022-07-01
A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02747342 2020-07-21
A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
Atridia Pty Ltd.
Phase 1 Completed
NCT04193319 2019-12-10
Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02759666 2019-09-19
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
Atridia Pty Ltd.
Phase 1 Completed
NCT02575651 2019-06-17
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03062982 2017-02-24
Food-Effect and Metabolism Study in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed